Dr Scott Arthur
MP for Edinburgh South West · Labour · United Kingdom
“Some colleagues have questioned the need for this debate. Like others, I welcome the news that we are going to proscribe the IRGC, but online, I have seen people who are basically antisemitic claiming that this is some kind of plot, that Jews are taking over the world, and that they were behind this decision.”
“I thank the right hon. Gentleman for giving way, particularly if he is drawing to a conclusion. Of course, the big “no confidence” debate was the 2024 general election. Before reflecting further on defence, can we go back to his enthusiasm for more exploration of oil and gas?”
“I appreciate that the Minister is substituting for another excellent Minister, my hon. Friend the Member for Washington and Gateshead South (Mrs Hodgson); I am sad that she is not here, because she is fantastic.”
“Absolutely. Yesterday I met with activists from Cancer Research UK just outside Parliament, before they came in. Cancer Research UK had around 100 activists there who had been touched by cancer, in all its shapes and forms, and although that big room was full of people who were full of energy, they were just a tiny part of the footprint o…”
“Exactly. In a former life, I was an academic. UKRI does at times engage with academics to fine-tune such questions. UKRI provides funding to universities, if needed, to bring the very best people to the UK either temporarily or on longer-term contracts to help to make a difference in the UK.”
“As I understand it, they plan to start a support group to focus specifically on lobular breast cancer, which will meet for the first time on 11 August. I wish them well in that endeavour and I am wearing my House of Hope badge today.”
The complete record
Every one of 601 lines we hold for Dr Scott Arthur, in date order, each linked to its source. Free to read, in full, without an account. Page 12 of 13.
“The principal there has refused to rule out compulsory redundancies, saying, “nothing is off the table”. In Aberdeen, voluntary redundancy schemes are open. Robert Gordon University is talking about losing 100 staff. It is expected that the Scottish Funding Council will say, that, as we heard earlier, over half the institutions in Scotland are running at a deficit. This is a crisis that demands urgent action. It is not just universities that are being short-changed; poor students are when it comes to loans for living costs. The living wage went up yesterday, which is good, but a single parent on the national minimum wage in Scotland working 37 hours per week will be earning £3,000 over the threshold for their child having full support at university, meaning that that single parent is expected to give the child £1,500 to attend university.”
“When clearing comes in the summertime and options are posted for Scotland’s universities, they are available only for students from outside Scotland. Even when Scottish students have better qualifications, they cannot get access to those places because the cap has been used up. The financial crisis is resulting in job losses right across Scotland. We heard about Dundee; the hon. Member for Dundee Central (Chris Law) is not in his place just now, but he outlined that 700 jobs are at risk there due to a £35 million deficit. The Scottish Government described the bleak outlook in Dundee as “troubling”—I think the staff there probably view it quite differently. The University of Edinburgh is looking at £140 million-worth of cuts over the next 18 months. That is 10% of its annual budget.”
“Scotland is unique in so many ways, but one of those ways is that it stands alone in the world with a Government who think they can grow the economy by cutting university funding and capping the number of places available to Scottish students. Our universities are at breaking point in Scotland. Funding per undergraduate student in Scotland is more than £2,000 less per student compared with England. Think about what that would mean for universities in England. Undergraduate education in Scotland—universities—cannot run at a profit; they cannot break even. They have to do other things. The cap on places is brutal. Since 2006, there has been a 56% increase in the number of applicants to universities, which is fantastic, but the number of refused entries has increased by 84%.”
“It is a pleasure to serve with you in the Chair today, Mr Vickers. I thank my hon. Friend the Member for Bedford (Mohammad Yasin) for introducing the debate so well. I should start by referring Members to the register of interests and saying I am a member of the University and College Union. I am also proud to say that I employ two university students in my office on a part-time basis. “Our education system in Scotland is crumbling, and it’s being allowed to happen. It’s becoming all too common to hear from university or college management that course closures are necessary and staff redundancy schemes unavoidable.” These are not my words, but those of Sai Shraddha Suresh Viswanathan, the current president of NUS Scotland.”
“I am interested to hear about the hon. Gentleman’s knowledge and experience of alternative fuels. He perhaps understands this statutory instrument better than I do, but I understood that it was about the weight of vehicles, and that an alternative fuel going through the internal combustion engine does not result in additional weight. Will any of the technologies that he is describing result in additional weight, and might they therefore fall foul of the limits in the regulations?”
“The number of young people treated for mental health issues in Scotland has dropped by 15%, so there are massive waiting lists but the treatment pace is dropping. Currently, about 4,000 people are waiting for treatment. This year, this Government set aside the biggest ever settlement for Scotland, and a large amount of that money has rightly been allocated to the NHS. I really hope that some of that money trickles down to mental health provision for young people, and specifically for eating disorders.”
“He outlined that the Scottish Government commissioned a review in 2020, and in 2024 created a template for eating disorder treatment that they can roll out across the country. I am slightly wary about that, because in Scotland we have lots of fantastic policies but implementation is often the issue— [ Interruption. ] I see Members nodding; they are well aware of that. Just £5 million has been allocated to the implementation of the strategy; none the less, it fills me with hope. The eating disorder strategy must build on mental health provision for young people that is fit for purpose. In Scotland, about 10% of young people wait more than 18 weeks after referral for their first mental health appointment.”
“I am not surprised that there is pressure on admissions. The number of people admitted in Scotland has increased substantially since 2007, and almost doubled during covid, so the system in Scotland is under real pressure. I spoke to the chief executive of my local NHS board about that, and she described the state of eating disorder treatment in the Lothians as at the absolute minimum acceptable level. I think we know what that means for many families. I then contacted the Cabinet Secretary for Health and Social Care—Scotland’s equivalent of my right hon. Friend the Member for Ilford North (Wes Streeting), if Members can imagine that—and he replied with lots of talk about frameworks, strategies and something alarming called a flexible funding stream, which did not fill me with too much hope.”
“I hope the Minister acknowledges that that is unacceptable. I am a Scottish MP, so I want to talk a bit about Scotland, where the situation is just as stressed as it is in England, but I will end with a slight glimmer of hope. Since I was elected last July, I have met people in Edinburgh South West who face eating disorders. I met a parent whose daughter had waited months for a consultation. They were filled with hope as the date arrived, only to find out that it was just a triaging slot to decide whether she should be referred to formal treatment months later. I met a parent whose daughter had been admitted to hospital and was released over a few days to see whether she could cope at home. She could not, but when she was taken back after the weekend, she was told that the bed space had gone, and that left the family in absolute crisis.”
“It is a pleasure to serve under you, Mr Stuart. I pay tribute to the hon. Member for Bath (Wera Hobhouse). When I was elected last year, I cared about eating disorders, but through her work on the APPG I have really come to understand them much more. I pay tribute to the secretariat, Hope Virgo—it is almost insulting to describe her as the secretariat, because she is such a powerhouse and really cares about this issue. I made the mistake of doubting the ambition of the APPG but, through the hon. Member for Bath and through Hope, we have made fantastic progress. Through them, I was shocked to find out that people are entering palliative care because of eating disorders. That is a disgrace and a sign that the whole system is failing the people—largely young people—facing this disease.”
“The hon. Member is of course right to talk about the economic impact of Brexit, but would it have been different if the vote had been won on our joining the customs union—a vote that the SNP abstained on?”
“It is a pleasure to serve under you today, Chair—I notice that you have got younger just in the last few minutes. [ Laughter. ] I hope it is orderly to flatter the Chair.”
“We should start making them from within universities, because that is where international collaboration works best. I also think that people were not wrong to vote for Brexit, but they were misled, so we have to be honest with them about that. We must explain why things have not unfolded as they were promised by people not in this room today, who should be owning up to the tragedy that they created. We have to be honest, frank and transparent with people, and we have to lead this debate. Hopefully, after the next election, we can build up to that referendum to rejoin.”
“I support this petition on rejoining the EU as soon as possible, but what does “as soon as possible” mean? My hon. Friend the Member for Walthamstow (Ms Creasy) explained that it could take many years of harmonisation, which is a real challenge for us; however, the bigger challenge is the division and acrimony that comes with referendums, because we would need a referendum to go back in. I have lived through the Scottish independence referendum and the Brexit referendum, both of which divided our communities and were toxic in many respects. They divided families, workplaces and even households, which is incredible. We have to start building the case right now if we are to avoid that situation happening again, and we must make the positive arguments for rejoining the EU.”
“Research funding from within the EU has got harder. I know it has improved slightly recently, but during the process it was difficult to build consortiums with a UK lead, and some partners were even worried about having UK universities within their consortiums, so we should not overlook the impact of that. Those problems only amplify the wider economic problems that Brexit has imposed on our economy, and they are felt more inside our university sector. I am pleased that the current Government are trying to rebuild relationships and get as close as possible with Europe. If we are doing that work and looking for trailblazers, that should be done within our universities, because there is much more that can be done to rebuild those relationships.”
“I should also mention that Patrick Thomson from the University of Strathclyde is shadowing me today—which so far has largely involved drinking coffee when I drink coffee. In higher education, Brexit has been problematic. Fewer students now come from the EU to Scottish universities. That is primarily not a money issue; it is about the diversity of thought within the classroom. It is a real problem and it leaves us all poorer. It is harder for universities to attract staff from the EU now. If we are serious about growing the economy, we need the best staff from around the world in our universities, and we should not be ashamed of that. I remember when we were going through the Brexit process, EU nationals were leaving universities and going back to Europe. That is a tragedy, and we should be ashamed of it.”
“I thank my hon. Friend the Member for Colne Valley (Paul Davies) for opening the debate so ably, and the many people in Edinburgh South West who signed this petition. I will speak briefly because what I was going to talk about has been well trod. Brexit has been an absolute tragedy for the UK, both economically and culturally. The Conservatives have taken a share of the blame today, along with Reform and its predecessor parties, but I have to be honest and say that when I think about how close the Brexit result was, I think about my party’s leadership at that time. More could have been done, so some blame should certainly be shared there. I came to this place last July from higher education, so I want to speak about the impact of Brexit on that sector. I do so in the context of my entry in the Register of Members’ Financial Interests.”
“I thank the hon. Gentleman for giving way. He suggests that we “go for it” on the customs union, but I think he was one of the MPs who abstained when he had that chance. Why the SNP abstained is a great mystery in Scottish politics. Can he explain why?”
“It was really humbling to meet her, and because she has that celebrity status, in my mind, I was also quite starstruck; I told her that it was like Taylor Swift entering my office. I resisted the temptation to exchange friendship bracelets with her, but she gave me a Solving Kids’ Cancer badge, which I am proud to wear today. Kira’s story is important because it reminds us that repurposing existing drugs can unlock great benefits, but those benefits can be delivered at scale only through additional medical research efforts and clinical trials.”
“I do not know a school or workplace in Edinburgh that did not help when they were given just three weeks to raise £500,000 for lifesaving specialist treatment in the USA. Now 21 and fundraising for other cancer sufferers, Kira is an example to us all. She owes her life to a lung cancer drug not typically provided to treat neuroblastoma and not yet generally available in the UK for that purpose, although I understand that Solving Kids’ Cancer is working on that. Kira appears on my social media so much, and is really well known in Edinburgh because of the fantastic campaign that she and her mum ran. She is a bit of a celebrity, if I can use that word. She came into my office recently to talk about the Bill.”
“Secondly, having a rare cancer should not mean being less likely to benefit from a medical breakthrough. According to Cancer52, in 2024, an astonishing 82% of patients with rare and less common cancers were not offered a clinical trial, and so were denied access to potentially lifesaving treatments. Often that is because such trials do not even exist, because there has been so little progress, and when they do exist, they are not always easy for patients to access. Let me give an example: there is a remarkable young woman in my constituency known as Kira the Machine. Kira has been living with neuroblastoma since she was 10. She has been through it all: a prognosis of inoperability, 26 rounds of chemotherapy and eight relapses. Her and her mum, Aud, are fundraising legends locally.”
“That is particularly true of the people I have been humbled to meet on my journey to speaking about the Bill today, including cancer patients, survivors, the bereaved and campaigners, all of whom want just one thing: justice. Although the healthcare system in the UK is founded on the notion of equality, fairness and justice, they believe that rare cancer patients are being overlooked. Their demand for justice covers three points. The first is that beating a rare cancer should not be less likely than beating other cancers. I have said that 47% of all UK cancer diagnoses each year are of rare and less common types. These patients already have the cards stacked against them, as they are 17% less likely to survive—an injustice caused by the relative lack of research and development in this field over many years.”
“This slow pace of change is not respected by these cancers, and it meant that Tilly missed her seventh birthday yesterday. I thank Jonathan for sharing Tilly’s story, and wish him all the best as he moves to Northern Ireland with Tilly’s mum and big sister Emily to start a new job. I thank Livingston’s Team Jak for their ongoing support for Tilly’s family and many others. Neither Jonathan nor I want to suggest that the Bill would have saved Tilly, but we hope that it will improve survival rates for others, and take them beyond the 50% rate given to Tilly. That is why Jonathan is here today, and why I am here today. Nobody told me that the most amazing thing about being an MP would be the people we meet almost daily, who want to make their community, our country or even the world a better place.”
“This was in September 2021, when face-to-face GP consultations were not possible. On visiting A&E, she was given ibuprofen. It was thought that she might have a virus. Six weeks later, she returned to A&E and was transferred to the cancer ward, where she was diagnosed with stage 4 neuroblastoma. On diagnosis, she was given a 50% chance of survival. Despite undergoing over a dozen rounds of chemotherapy and an operation, she sadly passed away about a year after her first symptoms appeared. Tilly was just four years old. Her father Jonathan, a headteacher in my constituency, is in the Gallery. He reached out to me after reading about the Bill. He explained his frustration that the development of new treatments for neuroblastoma has been moving at a glacial pace for too long. The same is true for many other rare cancers.”
“I beg to move, That the Bill be now read a Second time. We all know someone who has suffered from a rare cancer—a brain tumour, childhood cancer, pancreatic cancer, liver cancer, or one of the other cancers on a long list that are unfortunately all too familiar. Each of them may statistically be considered rare, but collectively they are anything but rare. Blood Cancer UK states that rare and less common cancers account for 47% of all UK cancer diagnoses—a staggering 180,000 a year. The irony of the Bill’s title is that so-called rare cancers are not rare. Common cancers deserve attention, but so too do rare cancers. I want to share an example of a family in my constituency who were confronted with a rare cancer. Tilly’s first symptoms were leg pains and loss of appetite.”
“I welcome that intervention; I think that was a leading question. Of course it is not good enough. I do not think that anybody here thinks that it is good enough, including the Minister. Unfortunately, at present there are very few clinical trials in this country for rare cancer treatments. Families such as Kira’s should not need to crowdfund for treatment overseas; we should be building the capacity here in the UK. Thirdly, having a rare cancer should not mean that a diagnosis is delayed when compared with diagnoses of other cancers. Rare cancer sufferers tell me that their symptoms are often less likely to be recognised, as doctors are less familiar with them.”
“Friend the Member for South Shields (Mrs Lewell-Buck), an observation that I have made on this journey is that so many of the people who have talked about late diagnosis have been women. That is purely anecdotal, but it seems to be the case. When I was at the Eve Appeal reception, the point was made that so many women are turned away; the GP tells them that they are hormonal, premenstrual or premenopausal.”
“Absolutely. Last week, I attended a reception for the Eve Appeal. I was really struck by the fact that early diagnosis was a big feature of what the charity was talking about, and I will come on to that in just a second. As a consequence of the lack of recognition of the symptoms of rare cancers, too many people are diagnosed too late. Last week, at an event hosted by the Brain Tumour Charity, I met Gabrielle and her wife and children. Gabrielle told me how the neurologist to whom she was initially referred did not recognise her brain tumour symptoms, and told her instead to go home, breathe into a paper bag and get some counselling. If only curing brain tumours was so easy. Reflecting on the comment made by my hon.”
“That will ensure co-ordination and accountability for the delivery of new cancer research in the UK. Secondly, the Bill would increase access to clinical trials via a service tailored to rare cancer patients. Through the Secretary of State’s new duties, that would be accomplished as part of the existing “Be Part of Research” registry, ensuring that all trials are registered in a single place. Thirdly, charities and clinicians tell me that more trials would be attracted to the UK if we had easier access to patient cohorts. Establishing a single database of willing patients would remove a significant burden on researchers in finding and verifying eligible people for clinical trials.”
“I will list four key measures and explain their impact: appointing a named responsible lead for the delivery of rare cancer research; creating a single registry of rare cancer trials; creating a single registry of rare cancer patients available for trials; and defining an evidence base for repurposing new cancer treatments. Let me explain in turn why these are important. First, the Bill would place a duty on the Secretary of State to facilitate and promote research related to rare cancer patients. The appointment of a national specialty lead for rare cancers in the National Institute of Health and Care Research would provide the Secretary of State with advice on the design and planning of research to facilitate collaboration between relevant parties.”
“With smaller patient populations, there is an increased logistical challenge in bringing patients together. Currently, we are lacking a sufficient development strategy and there is no single source of patient data, meaning companies must undertake the costly endeavour of finding patients and verifying eligibility. Even if they succeed in running a clinical trial and a drug proves to be an effective treatment, companies face the challenge of selling a drug developed at great expense to a small market. Ultimately, these companies exist to return a profit for their shareholders. Given a choice between investment in potential treatment for a rare cancer or a more a common one, too often rare cancer patients lose out. Having set out the challenges faced by those diagnosed with rare cancers, let me now address what the Bill aims to accomplish.”
“However, rare cancer patients are being left behind, and I need to explain why. It is not due to a lack of effort by charities or those affected by the disease. In fact, in the Gallery today are members of some incredible charities who are fighting against rare cancers in what is often an uphill battle. I thank them for their hard work in helping me to develop the Bill—they really have helped me—which aims to address the injustices faced by rare cancer patients and their families. For all the people I have met from the charities, their work is much more than a job for them; it is about making a difference to people’s lives, improving survivability and supporting families. The reason for the uphill battle is that research into rare cancer is much less appealing to pharmaceutical companies when compared with more common conditions.”
“Friend the Member for Mitcham and Morden that I learned that only 25% of glioblastoma patients live beyond 12 months after diagnosis, and only one in 20 survive beyond five years. Despite that awful prognosis, as for other rare cancers, the drugs to treat glioblastoma have not changed in decades. That is why I knew in my heart that I needed to introduce a Bill that would help equip those working hard to fight against glioblastoma, and all rare cancers, with the tools they need to further their efforts and, ultimately, save lives. Over the past 15 years, thanks to the dedicated work of charities, survivors and researchers, we have seen a 10% rise in survival rates for those diagnosed with cancer. Globally, new treatments are being developed and rolled out to patients, improving outcomes and saving lives in our NHS every single day.”
“Once we entered the new year, he began to lose his mobility, and eventually he was admitted to Adamson hospital in Cupar. In 2018, surrounded by his wife and daughters, Ivor died peacefully, eight months after his first symptoms. He had a good life and his daughters are a fantastic legacy to him, as well as all the pupils he taught at school. However, as a physically fit man, Ivor should have lived longer: he should have lived to see his birthday last weekend, and if he had done so, he would not have missed two of his grandchildren getting married and his first great-grandchild, Fraya, being born in December last year. I assumed that he had been unlucky with glioblastoma. It was not until I met my hon.”
“In time, Ivor and Sylvia had grandchildren: Andrew, our daughter Ruth, Hannah, Matthew, our son Ben, Rory and Sophie. Ivor was not a passive grandfather; he worked hard to ensure his grandchildren flourished. In September 2017, Ivor began having problems with his speech. My wife Audrey, an NHS nurse, was concerned that it might be a sign of dementia. We all hoped that that was not the case. Following an MRI scan in the November, we received the devastating news that Ivor had glioblastoma. At Christmas he was still very much himself and enjoyed the festivities. Ivor never had a pound of fat on him, but when it came to Christmas time he really did hoover up the food and enjoyed the Christmas meal. It was great to see him that Christmas, but we did feel that it would be his last.”
“I know her to be a formidable woman who in this context is driven by glioblastoma taking her sister, Margaret. I did not know her sister at all, which is my loss, but I do know that she shaped my party and she helped change our country for the better, and I know above all that she was loved by her sister. Glioblastoma is typical of so many rare cancers, and it started me on this journey so I want to talk about it further. My father-in-law, Ivor Hutchison, was a dignified man but glioblastoma did not respect that. He was a technical teacher at Bell Baxter high school in Fife. He was married to Sylvia and they have four daughters, Denise, Iona, my lovely wife Audrey who is in the Gallery —I have just embarrassed her—and Sarah.”
“Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh). Just last week I met Oriana, one of the people who emailed me. It was incredibly moving to meet her; it took me right back to the start of this journey. I posted on my Facebook page about meeting her, and straight away somebody said that they knew her and that she had helped them when their family had been faced with glioblastoma. That is a reminder that so many people affected by these conditions turn their loss into something really positive and help other people. My hon. Friend’s campaign relates to glioblastoma, a type of tumour that took my father-in-law. I felt that the stars had aligned for me. I really do mean that; I really did get that feeling. I want to pay tribute to my hon. Friend. [Hon. Members: “Hear, hear.”] More, more!”
“My Bill focuses on the first two points, but I want to acknowledge the need to improve diagnosis, because of comments that have already been made. I am sure that will feature in the cancer plan. I am the first to admit that, when I was successful in the private Member’s Bill ballot, I found it daunting as a new MP. I thought I had some really good ideas for a Bill, but as soon as my ping-pong ball was picked from the goldfish bowl, I was inundated with calls from constituents, charities and lobbyists, each telling me that their cause was better than any I could think of. I considered many worthwhile causes over the following days, but while having a coffee in Colinton Mains Tesco in Edinburgh South West, I received emails from members of the public who support the campaign of my hon.”
“I thank my hon. Friend and office neighbour for making that point, which was also made by Eve Appeal. I cannot remember the statistics, but there is a stark difference. I talked about this issue when I met the Minister yesterday and she gently pointed out to me that it is not just in healthcare where women are dismissed as hormonal, premenstrual and so on. I thanked her for reminding me of that in the gentlest possible way. It is a cruel irony that rare cancers such as Gabrielle’s tumour are typically less survivable, making early diagnosis even more important. Rare cancer patients require early, not later, diagnosis. I have spoken about poor outcomes, lack of progress in developing treatments and late diagnosis.”
“We often hear about how drug development for one cancer can be used to defeat another; that is what Kira relies on right now. My Bill aims to build a foundation for industrialising that approach via incentives. The EU has a similar system for incentivising the testing of drugs for paediatric use that have already been approved for adult use, so the approach has been tried and tested. Together, these measures will ensure that we have leadership in Government and will remove the barriers to running new clinical trials that researchers and pharmaceutical companies face.”
“The challenge is devolution. I am a huge fan of devolution, but often the UK is at its best when it works together, particularly on healthcare. I hope that in time we will see progress and the nations will work together. I do not want to overstate this, but there have been discussions across the UK about how we could work together on the issue, so perhaps the answer is, “Watch this space.” The Bill’s fourth measure is to trigger a review by the Government of the orphan drug regulations, to examine how they can be reformed to better incentivise pharmaceutical companies to invest in clinical trials for rare cancers. Specifically, it will consider how incentives could be provided to pharmaceutical companies to trial the repurposing of new cancer treatments.”
“Tilly and Ivor deserved a better chance of beating the cancer inside them, and those who are yet to be diagnosed deserve a better chance of a full life. Let us pass this Bill today and work across the UK to take the fight to rare cancers and save lives. I commend this Bill to the House.”
“It was great to see the Minister as well, and I have to say—this is not a trivial point—that the cake there was absolutely fantastic. I do not doubt that when I get back to my office and check my emails, more organisations will have got in touch to say that they want to support what we are doing today. I know that many Members in the Chamber today will have deeply personal stories to tell, on their own behalf and on behalf of their constituents. I look forward to hearing those testimonies as we debate this Bill, because it is so important to give those people a voice. I will conclude by saying that the Bill we are debating today has a real chance of making a difference. For too long, rare cancer patients have been left on the sidelines without significant advancement—this cannot go on.”
“It is supported by Maggie’s, Shine Cancer Support, Solving Kids’ Cancer, the British Liver Trust, Blood Cancer UK, Radiotherapy UK, Leukaemia UK, CCLG—the Children and Young People’s Cancer Association, CLL Support, Neuroblastoma UK, Salivary Gland Cancer UK, Neuroendocrine Cancer UK, Melanoma Focus, Myeloma UK, Hope For Tomorrow, Alike, Yorkshire Cancer Research, Young Lives vs Cancer, the Tessa Jowell Foundation, the UK Mastocytosis Support Group, the Bone Cancer Research Trust, the Neurosciences Foundation and the Eve Appeal. The Eve Appeal had a fantastic reception last week, and when I went along to it, having its support felt like a real tipping point in the progress we are making in building support for the Bill.”
“Inflammatory breast cancer accounts for 2% of breast cancer diagnoses in the UK each year, but 10% of the deaths. The Bill is also supported by Target Ovarian Cancer, Brainstrust, AMMF—the Cholangiocarcinoma Charity, the Urology Foundation, the Tessa Jowell Brain Cancer Mission, Action Kidney Cancer and Sarcoma UK, which I met this week. I have a friend with that cancer, and it is a fantastic organisation that I hope to work more with in the future.”
“The Less Survivable Cancers Taskforce says that the Bill “could be a truly transformative moment in the UK’s approach to research for rare and less common cancers.” My friends at the Brain Tumour Charity say that the Bill “is a framework for tangible, impactful change.” At this point, I have to mention my daughter’s connection with the Brain Tumour Charity. She is running a marathon in May to raise funding for it, and I wish her well. [Hon. Members: “Hear, hear.”] Thank you. Let me list some of the other groups that support the Bill. They include Pancreatic Cancer UK, which has been absolutely fantastic in its support for what we are doing; Cancer52, an organisation that represents more than 100 groups; the Angel Mums; the Grace Kelly Childhood Cancer Trust; and the Inflammatory Breast Cancer Network UK.”
“Absolutely. There is fantastic expertise in our universities across the UK; as I say that, I have to refer hon. Members to my registered interests because of my connections with the university sector. There is much more that we can do to attract the best researchers to the UK and build capacity in UK universities. The Bill will provide greater accountability for the delivery of new research, but please do not just take my word for it. Brain Tumour Research has described it as “essential for a brain tumour cure”. I did not feel any pressure at all when I read that quote! No, it was quite daunting, to be honest.”
“In all the contributions today, we have heard evidence that people with a rare cancer diagnosis face great injustice, because their chances are so much slimmer and they face so much uncertainty. We have shown that we want change. We are not just being angry; we are using that anger to get even, which is really important. We talk in this Chamber, but often there is no action. Today we have talked and agreed, and hopefully there is going to be action.”
“Privately, there have been a few Sir Humphrey moments, but those from the Department have been absolutely fantastic, and that was very clear yesterday when I met the Minister. I thank the charities that backed the Bill. They did not just back it; they helped get it to where it is. They were not just backing a finished product; they influenced and shaped it. I think that is why so many people are here to support it. I thank the staff in the Public Bill Office for their patience and so much more, and I thank the staff in my office. I think Noel and Solomon are here today, but it is a team effort. Back in Edinburgh are Lucie, Salim, Xavier, Evie and Hannah. [Hon. Members: “Hear, hear.”] They deserve that.”
“I thank the Whips and the Speaker’s Office for managing the debate sensitively, because this is quite a difficult subject, and I thank you, Madam Deputy Speaker, because it was you who pulled my ping-pong ball from the goldfish bowl. It was very skilfully done. I wish I had time to thank everybody who spoke in the debate. Sadly, I do not, but they have my thanks and respect. They have done a great job of thanking each other as the debate has proceeded, so I thank them all. I will watch the debate again over the weekend, because it has been quite incredible and quite moving. I thank our colleagues from the Department of Health and Social Care, who are in the officials’ box. They have been fantastic. Without them, this Bill would not have happened.”